Shots:

• The approval is based on P-III clinical studies evaluating Amzeeq (topical foam- 4%) versus vehicle in 2-418 patients aged ≥9yrs. with inflammatory lesions of non-nodular moderate to severe acne vulgaris
• The P-III studies resulted in improvement in reduction of inflammatory lesions and improvement in IGA treatment success defined as score of 0 ("clear") or 1 ("almost clear") and at least a two-point decrease from baseline- well-tolerated with no AEs
• Amzeeq (FMX101) is the first topical minocycline to be approved by the FDA for any condition and is indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients with its anticipated availability in the US in Jan’2020

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance